Navigation Links
Once-Promising Heart Failure Drug Fails in Trial
Date:10/7/2010

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Oct. 6 (HealthDay News) -- A new experimental drug for treating patients who have acute heart failure plus kidney failure did not show any overall benefit, indicating that the future of this particular drug, called rolofylline, is over.

"I think this is the end of the story for this drug," said Dr. Barry Massie, lead author of a study appearing in the Oct. 7 issue of the New England Journal of Medicine. "There was a very promising pilot trial but these results . . . were neutral. I am disappointed," he said.

The results were presented last year at the European Society of Cardiology meeting. Shortly before that, drug company Merck, which has been developing the medicine and which funded this study, announced that it would not be filing for U.S. Food and Drug Administration approval for rolofylline.

Rolofylline is known as an A1-receptor antagonist and is intended to make diuretics work more effectively.

Other drugs in the same class of medications that were developed by other companies have met with similarly disappointing results after promising early results, said Massie, who is chief of the cardiology division at the San Francisco VA Medical Center and professor of medicine at the University of California, San Francisco.

He explained that kidney problems are a major complication of heart failure and "those patients who develop renal [kidney] failure in the course of treatment have a much higher hospital admission and death rate."

This may be at least partly because patients are taken off of certain cardiac medications in order to improve kidney function.

"This is sort of a perfect storm," Massie said.

For this study, just over 2,000 patients who had been hospitalized for acute heart failure and kidney problems were randomly assigned to receive a placebo or 30 milligrams of rolofylline daily intravenously. Treatment lasted for up to three days.

Rolofylline did not prolong survival or improve heart failure or kidney function when compared with the placebo.

And in contrast to the placebo group, some patients taking rolofylline had seizures, indicating that the drug was able to cross the blood-brain barrier. Seizures are a potential side effect for this class of drugs.

"[We] had hoped that the drug didn't cross the blood-brain barrier," Massie said.

One expert was similarly disappointed with the study results.

"Rolofylline certainly does not seem to have benefit in terms of risk of mortality (or death) and hospital readmission," noted Dr. Tara Narula, a cardiologist with Lenox Hill Hospital in New York City. "At this point, unfortunately, we're left with what we have in our arsenal, which we've [already] had for many years."

That includes IV loop diuretics, ACE inhibitors and beta blockers, she said.

More information

There's more on heart failure at the American Heart Association.

SOURCES: Barry M. Massie, M.D., chief, cardiology division, San Francisco VA Medical Center and professor of medicine, University of California, San Francisco; Tara Narula, M.D., cardiologist, Lenox Hill Hospital, New York City; Oct. 7, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Workplace Noise Tied to Heart Disease Risk
2. Testosterone Could Boost Health of Heart Failure Patients
3. Dental Care Linked to Heart Health in Older Women
4. Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment
5. Women who get dental care have lower risk of heart disease, says study
6. WUSTL awarded $18 million to treat heart, lungs with nanotechnology
7. Researchers use CT to predict heart disease
8. ESC announces new initiatives for workplace heart health programs
9. Disparities in heart attack treatment may begin in the emergency room
10. Molecular playbook for halting heart failure risk factor uncovered
11. Surgery May Be Best for Irregular Heartbeat in Young
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Once-Promising Heart Failure Drug Fails in Trial
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
Breaking Medicine Technology: